度洛西汀、文拉法辛及阿米替林治疗精神分裂症后抑郁的对照研究

【摘要】 目的比较度洛西汀、文拉法辛及阿米替林治疗精神分裂症后抑郁的临床疗效和安全性。方法将73例精神分裂症后抑郁的患者分为度洛西汀治疗组,文拉法新治疗组及阿米替林对照组,使用卡尔加里精神分裂症抑郁量表(CDSS)、汉密顿抑郁量表(HAMD17)、简明精神病评定量表(BPRS)及副反应量表(TESS)于治疗前及治疗后2、4、6周末分别评定疗效和副反应。结果度洛西汀、文拉法辛及阿米替林组间的CDSS和HAMD评分差异无统计学意义。度洛西汀、文拉法辛治疗组的不良反应较阿米替林对照组要少且轻。结论度洛西汀、文拉法辛治疗精神分裂症后抑郁的临床疗效与阿米替林相当,不良反应少。更多还原

【Abstract】 Objective To compare the efficacy an safety of duloxetine,vanlafaxine and amitripryline in the treatment of post-schizophrenia depression.Methods Seventy-three cases with post-schizophrenia depression were randomly divided into duloxetine group,vanlafaxine group and amitripryline group,curative effects and side effects were evaluated with CDSS,HAMD,BPRS and TESS before treatment and 2,4,and 6 weeks.Results There existed no singnificant difference in the scores of CDSS and HAMD,between the 3 groups.The side effects of duloxetine and vanlafaxine were less than amitripryline group.Conclusion Duloxetine and vanlafaxine share the same curative effects of amitripryline in the treatment of post-schizophrenia depression,and high safety and less side effects.更多还原